2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.
Sagar Lonial, MD, FACP, chief medical officer, Winship Cancer Institute of Emory University, professor and chair, Department of Hematology and Medical Oncology, Anne and Bernard Gray Family Chair, Emory University School of Medicine, discusses the management of belantamab mafodotin-blmf (Blenrep)–related keratopathy in patients with relapsed/refractory multiple myeloma.
Prior to administering the first dose of belantamab mafodotin to patients with relapsed/refractory multiple myeloma, clinicians should establish a relationship with an ophthalmologist or an optometrist, as a close collaboration with them will be important to manage eye-related toxicities, Lonial says. Moreover, this is something that everyfirst-year optometrist or ophthalmology residents can be part of this collaboration within the first week of their residency or training, as the required eye exams are not complicated, Lonial explains. Ultimately, the eyecare specialists will need to be able to quantify what potential toxicities are observed by grading them, Lonial explains.
Building the partnership and maintaining an open line of communication between medical oncologists and eyecare specialists is key so the ophthalmologist or optometrist knows exactly what to look for with regard to belantamab mafodotin–related toxicities. This, in turn, helps optimize care for patients receiving the treatment, Lonial concludes.